DeepMed Research

FOX CHASE CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1904-01-01

Employees: -

Market Cap: -

Website: http://www.foxchase.org

Clinical Trials

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Phase 2

Active, not recruiting

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Ribociclib
Drug: Everolimus

First Posted Date: 2017-04-14

Last Posted Date: 2025-04-04

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 48

Registration Number: NCT03114527

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Safety and Activity of Digoxin With Decitabine in Adult AML and MDS

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: Decitabine
Drug: Digoxin

First Posted Date: 2017-04-13

Last Posted Date: 2021-03-16

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 1

Registration Number: NCT03113071

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Jeans Hospital, Philadelphia, Pennsylvania, United States

Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC

Phase 2

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: Regorafenib
Drug: 5-FU
Drug: Leucovorin

First Posted Date: 2017-04-04

Last Posted Date: 2022-02-07

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 2

Registration Number: NCT03099486

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer

Phase 2

Terminated

Conditions: Endometrial Cancer

Interventions: Drug: ONC201

First Posted Date: 2017-04-04

Last Posted Date: 2024-12-24

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 19

Registration Number: NCT03099499

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Observation Study of Patients With Non-Small Cell Lung Cancer and Esophageal Cancer Treated With Chemo-Radiation Followed by Surgery

Completed

Conditions: Lung Cancer
Esophageal Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Radiation: Radiation Therapy

First Posted Date: 2017-03-29

Last Posted Date: 2021-10-12

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 6

Registration Number: NCT03095209

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer

Phase 1

Recruiting

Conditions: Lung Cancer
Esophageal Cancer

Interventions: Radiation: Pulsed Low Dose Radiation
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2017-03-29

Last Posted Date: 2023-05-23

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 40

Registration Number: NCT03094884

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Improving the Approach to and Management of the Older Metastatic Breast Cancer Patient

Not Applicable

Completed

Conditions: Metastatic Breast Cancer

Interventions: Behavioral: Didactic session
Behavioral: Comprehensive Geriatric Assessment

First Posted Date: 2017-01-02

Last Posted Date: 2020-03-02

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 100

Registration Number: NCT03007641

Locations: 🇺🇸
AtlantiCare Cancer Care Institute, Egg Harbor Township, New Jersey, United States
🇺🇸
Bozeman Deaconess Hospital, Bozeman, Montana, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 2 locations

Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas

Phase 2

Terminated

Conditions: Soft-tissue Sarcoma

Interventions: Drug: TAK-228

First Posted Date: 2016-12-09

Last Posted Date: 2022-10-14

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 6

Registration Number: NCT02987959

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder

Not Applicable

Active, not recruiting

Conditions: Urothelial Carcinoma

Interventions: Procedure: Radical Cystectomy

First Posted Date: 2016-11-21

Last Posted Date: 2024-06-18

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 65

Registration Number: NCT02968732

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

Phase 1

Terminated

Conditions: Relapsed or Refractory Solid Tumors
Nonsmall Cell Lung Cancer

Interventions: Drug: Lenalidomide
Drug: Pembrolizumab

First Posted Date: 2016-11-15

Last Posted Date: 2021-12-30

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 3

Registration Number: NCT02963610

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy